|
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) Clinical research trials and Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL). Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)  Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
For Condition: Leukemia, Lymphocytic, Chronic
Status: Recruiting
Sponsor(s): Biogen Idec ,
Synopsis: To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Signed IRB-approved informed consent. - Greater than 18 years of age - Proof of CD23+ CLL or small lymphocytic lymphoma (SLL) - Progressive disease after at least 1 course of chemotherapy - Acceptable hematologic status, liver function, renal function, and pulmonary function - Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment Exclusion Criteria: - Previous exposure to IDEC-152 or other anti-CD23 antibodies - Presence of HIV infection or AIDS - Serious nonmalignant disease - Active uncontrolled bacterial, viral or fungal infections. - Clinically active autoimmune disease - Pregnant or currently breast feeding
Total Enrollment:
Location and Contact Information:
Biogen Idec Incorporated *Recruiting*
San Diego, California, 92121
United States
Recruiting
Additional Information:
Study ID Numbers: 152-20;
Study Start Date: September 2002
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046488
Other Leukemia, Lymphocytic, Chronic Studies:
1. A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
2. Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
3. A Pilot Study of Pivanex in Patients with Chronic Lymphocytic Leukemia
4. A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
5. Study of ONTAK in patients with B-Cell Chronic Lymphocytic Leukemia (CLL)
Related Studies:
Other Leukemia, Lymphocytic, Chronic Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
|
|
|
|
|
|
|
|
